Orthocell Ltd (ASX:OCC) is a regenerative-medicine company whose lead product, Remplir, is a collagen nerve-repair wrap used by surgeons to protect and support peripheral nerves during surgery. After securing United States Food and Drug Administration clearance, Orthocell has been rolling Remplir out across the large United States surgical market, the key driver of its growth story.

Record Revenue and accelerating United States adoption have framed the question of whether the market is underestimating this healthcare growth story.

Latest Development

For FY26, Orthocell reported record revenue of approximately A$13.2 million, up 44%, with fourth-quarter revenue of about A$3.8 million. In the United States, Remplir sales in the June quarter were around A$330,000 from 119 units, with 70 United States hospitals now purchasing the product, up 27%, and 76 surgeons using it, up 55%, alongside 44 hospital value-analysis-committee approvals, up 38%.

The company finished FY26 with available funds of approximately A$44.1 million, comprising A$9.4 million of cash and A$34.7 million in securities and term deposits, and reported a modest operating cash outflow, giving it a strong Balance Sheet to fund the rollout.

What Could Drive the Shares Next?

Catalysts include continued growth in United States hospitals, surgeons and value-analysis-committee approvals, rising Remplir unit sales, and any expansion of its regenerative-medicine pipeline. Evidence that United States adoption is compounding would be the most powerful driver.

A clear trajectory toward scaled, profitable United States revenue would support the case that the market is underestimating the story.

Risks Investors Should Watch

The United States rollout is still early, and adoption depends on winning hospital approvals and surgeon preference, which takes time. Competition in nerve repair and surgical products exists, and the company is still investing ahead of scaled revenue.

Execution on the United States commercial build-out is the key risk, alongside the pace at which approvals convert into repeat sales.

Investor Takeaway

Orthocell delivered record FY26 revenue of about A$13.2 million, up 44%, with rising United States hospital and surgeon adoption of Remplir and a strong balance sheet. Whether the market is underestimating the story depends on that United States adoption continuing to compound. Hospital and surgeon growth, Remplir sales and cash are the things to watch.